Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam ED90 for reducing preoperative anxiety in children aged 1–6 years
ChiCTR2500098747Phase 4Completed
- Sponsor
- The Third Affiliated Hospital of Zhengzhou University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in preoperative anxiety (2 arms), sponsored by The Third Affiliated Hospital of Zhengzhou University. Primary endpoint: ED90 (90% effective dose of remimazolam for anxiety reduction). Started Apr 2025; status: completed.
02
Drugs
remimazolam
03
Conditions
preoperative anxiety
Beyond the preview
Go deeper on ChiCTR2500098747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098747.